CM10蛋白质芯片在乳腺癌诊断与随访中的应用.doc

  The Application of the CM10 Proteinchip in the Diagnosis and Follow-up of Breast Cancer# 5 10 15 20 25 30 35 40 Hu Yue1, Yu Jiekai2* (1. Department of Surgical Oncology, the Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, 310009; 2. Cancer Institute, the Second Affiliated Hospital of Zhejiang University, School of Medicine, Hangzhou, 310009) Abstract: Introduction: Breast cancer lacks good serum tumor markers for its diagnosis, follow-up and evaluation of curative effect. Our research aimed to use SELDI-TOF-MS and CM10 ProteinChip to detect the serum proteomic patterns in patients of breast cancer, screen the biomarker candidates, build and validate the diagnostic models and evaluate its clinical value in surveillance and follow-up after operation. Methods: SELDI-TOF-MS technology and CM10 ProteinChip were used to detect the serum proteomic patterns of 63 breast cancer patients and 40 healthy women. ZJU-PDAS software was used to screen the biomarker candidates and build the diagnostic models. The best model was blind validated in the subsequent-recruited 23 patients and 20 healthy women. Another 16 serum samples were detected to evaluate its significance in surveillance and follow-up after surgery. Results: The best model was composed by two protein peaks (3.9 KDa / BC1 and 5.6 KDa / BC2) with its sensitivity and specificity of 87.30% (55/63) and 95.00% (38/40) respectively. The sensitivity and specificity in the subsequent blind validation of new cases were 95.65% (22/23) and 85.00% (17/20) respectively. The diagnostic efficacies were the same to the patients of different stages (P0.05). BC1’s expression increased while BC2’s decreased after operation (P0.05). BC2’s expression in the patients with recurrence or metastasis was higher than that in the tumor-free survivors (P0.05). Conclusions: This method shows its potential in diagnosis, surveillance and follow-up after operation as well as screening of novel and better biomar